
This study determined the clinical outcomes of different immune checkpoint inhibitor (ICI) combinations for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. A total of 85 NSCLC patients with EGFR mutations received ICI combinations after resistance to prior EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The study found that patients who received ICIs combined with anti-angiogenic therapy had longer progression-free survival (PFS) and overall survival (OS) than patients who received ICIs combined with chemotherapy. Patients with L858R mutations or without T790M mutation benefited more from ICI combinations. Patients with prior first-generation EGFR-TKI resistance had longer PFS and OS than prior third-generation EGFR-TKI resistance patients.
Like
Save
Share